Gilead Sciences, Inc. today announced positive topline results from the Phase 3 ARTISTRY-1 trial. The open-label trial evaluated the treatment responses of adults with HIV who are virologically ...
A tailored approach with rapid needs assessment before and during implementation to address local testing site barriers in ...
SHELTON, CONNECTICUT / ACCESS Newswire / November 11, 2025 / NanoViricides, Inc. (NYSE American:NNVC) (the “Company”), today announced that it has entered into a securities purchase agreement with a ...
Anura Kumara Dissanayake’s 2026 Budget speech, while breaking symbolically from tradition, reveals a deeper continuity with ...
Strategic process -- Formal engagement with Evercore concluded; current focus is on Phase III clinical execution, with ...
Delcath Systems, Inc. , ("Delcath" or the "Company") an interventional oncology company focused on the treatment of primary and metastatic liver cancers, today announced the publication of results ...
Create your free account and save 20% sitewide with our Black Friday sale. Access expert insights, powerful tools, and data-driven research—all at a special price.
Attending these events teaches me more about public policy than reading a pile of government reports. At the first event, the ...
The Chosun Ilbo on MSN
Genetic Testing Advances Herald 'Super Baby' Era
Predictive indicators for whether a child will be vulnerable to certain diseases after birth, as well as their future height, ...
Detailed price information for Gilead Sciences Inc (GILD-Q) from The Globe and Mail including charting and trades.
Gilead Sciences has developed an industry-leading HIV portfolio in recent years with its megablockbuster daily treatment ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback